Please read this page before participating in this activity. At the bottom of the page, select “I have read these instructions and understand them,” and then click “Begin Activity.”


Overview

CME Credit Available: Maximum of 13.25 AMA PRA Category 1 Credits™
Release Date: July 28, 2011
Expiration Date: July 29, 2012

The 14th Annual Clinical Conference for the Ryan White (RW) HIV/AIDS Program, Parts A, B, C, D, and F was held June 27-29, 2011, at the Marriott Tampa Waterside in Tampa, Florida. The Clinical Conference offered a rewarding and productive exchange of essential updates and training. New grantees had the valuable opportunity to discuss cases with experts and network with other RW Program clinicians.

The goal of the meeting was to provide a comprehensive and timely overview of HIV treatment issues and current strategies in HIV medical care for prescribers in RW HIV/AIDS Program, Parts A-, B-, C-, D-, and F-funded clinics/programs. You may view and download a copy of the Clinical Conference syllabus and key slides at http://www.iasusa.org/rwprogram2011.

The Clinical Conference is planned and supported in collaboration with staff from the HIV/AIDS Bureau (HAB), Health Resources and Services Administration (HRSA) of the US Department of Health and Human Services, and Southeast AIDS Training and Education Center (SEATEC). This CME program is sponsored by the IAS–USA under the HRSA contract number HHSH250200900010C.

The Webcast activity consists of audio and visual recording of 17 live presentations. To receive CME credit, please read the overview and follow the link to the presentation.

To view a particular presentation, the learner should click on the presentation title. The Webcast will open in a separate window. The learner may view as many presentations in this activity as he or she chooses. The learner agrees that slides are for webcast viewing only. He or she will not copy, alter, or change these Webcast presentations in any way.

Once 1 or more presentations have been reviewed, learners may link to the CME evaluation from a link at the top of the main index of presentations. This is required for credit. Instructions for the evaluation are found on that page.


Needs and Objectives

Upon completion of the Clinical Conference, participants will be able to do the following:

• Design antiretroviral treatment strategies that consider new and upcoming data
• Describe current possibilities for curing HIV disease
• Monitor and refer HIV patients with oral manifestations
• Formulate appropriate strategies for managing tuberculosis, hepatitis C virus, or sexually transmitted infections in patients with HIV infection
• Identify patients with personality disorders
• Design interventions for alcohol use and abuse among the HIV-infected population
• Describe the key clinical issues associated with cognitive, metabolic, renal and cardiovascular complications in individuals with HIV infection
• Describe biomedical and behavioral methods to prevent HIV infection
• Describe the impact of the National AIDS Strategy and Federally Qualified Health Centers on Ryan White HIV/AIDS clinicians
  

CME Credit

CME Accreditation Statement
This Clinical Conference Webcast is sponsored by the IAS–USA. The IAS–USA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
The IAS–USA designates this internet enduring material activity for a maximum of 13.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Intended Audience for CME Credit

This online CME activity is designed for physicians, physician assistants, nurse practitioners, and other direct clinical care providers who are actively involved in HIV patient care in Ryan White funded programs. Specifically, these activities have been designed for physicians who:

• Have a solid, working knowledge of HIV disease management
• Provide comprehensive or specialty care for patients with HIV/AIDS
• Are currently active in HIV/AIDS research

Course Faculty

Co-Chairs

Laura W. Cheever, MD, ScM
Deputy Associate Administrator
Chief Medical Officer, HIV/AIDS Bureau
Health Resources and Services Administration
Rockville, Maryland

Polly E. Ross, MD
Medical Director
Western North Carolina Community
Health Services Inc
Asheville, North Carolina

Michael S. Saag, MD
Member, Board of Directors (Volunteer)
IAS–USA
Professor of Medicine
Jim Straley Chair in AIDS Research
Director, Center for AIDS Research
University of Alabama at Birmingham
Birmingham, Alabama

Faculty

Sanjeev Arora, MD
Vice Chairman
Clinical Affairs, Internal Medicine
The University of New Mexico
Albuquerque, New Mexico

Jeffrey Beal, MD
Clinical Director and Associate Professor
Florida/Caribbean AETC
Tampa, Florida

Matthew T. Burke, MD
Senior Clinical Advisor
Office of Quality and Data
Bureau of Primary Health Care
Health Resources and Services Administration
Rockville, Maryland

Kenneth G. Castro, MD
Director, CDC’s Division of Tuberculosis Elimination
Assistant Surgeon General
US Public Health Services
Atlanta, Georgia

Geetanjali Chander, MD, MPH
Assistant Professor of Medicine
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Laura W. Cheever, MD, ScM
Deputy Associate Administrator
Chief Medical Officer, HIV/AIDS Bureau
Health Resources and Services Administration
Rockville, Maryland

David B. Clifford, MD
Melba and Forest Seay Professor of Clinical Neuropharmacology in Neurology
Washington University School of Medicine
Saint Louis, Missouri

Emily Erbelding, MD, MPH
Deputy Director, Division of AIDS
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Bethesda, Maryland

Joseph J. Eron, Jr., MD
Professor of Medicine
Principal Investigator
AIDS Clinical Trials Unit
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Jeffrey D. Hill, DMD
Associate Professor
University of Alabama School of Dentistry
Director, 1917 Dental Clinic
University of Alabama School of Medicine
Birmingham, Alabama

Jeanne M. Marrazzo, MD, MPH
Professor of Medicine
University of Washington
Seattle, Washington

Wendy S. Post, MD
Associate Professor of Medicine and Epidemiology
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Kristen M. Ries, MD
Professor Emerita
University of Utah School of Medicine
Salt Lake City, Utah

Polly E. Ross, MD
Medical Director
Western North Carolina Community
Health Services Inc
Asheville, North Carolina

Michael S. Saag, MD
Member, Board of Directors (Volunteer)
IAS–USA
Professor of Medicine
Jim Straley Chair in AIDS Research
Director, Center for AIDS Research
University of Alabama at Birmingham
Birmingham, Alabama

Robert F. Siliciano, MD, PhD
Professor of Medicine
Director of MD PhD Program
The Johns Hopkins University School of Medicine
Principal Investigator
Howard Hughes Medical Institute
Baltimore, Maryland

Victor G. Valcour, MD
Associate Professor of Geriatric Medicine
Memory and Aging Center
University of California San Francisco
San Francisco, California

S. Todd Wallenius, MD
AAHIVM HIV Specialist
Director, Behavioral Health Services
Western North Carolina Community Health Services
Asheville, North Carolina

Christina M. Wyatt, MD
Assistant Professor of Medicine
Mount Sinai School of Medicine
New York, New York



Disclosure of Financial Affiliations

In the interest of maintaining the independence of its continuing medical education (CME) activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education, the IAS–USA requires all persons with control of content (ie; faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they (or their spouses or partners) have had with commercial companies within the past 12 months of the date of this Web-based CME conference. Any real or apparent conflicts of interest of those parties are resolved prior to the education activity being delivered. Individuals who refuse to disclose financial interests may not participate in the CME activity.

IAS-USA Board of Directors

Constance A. Benson, MD
Dr Benson has no relevant financial affiliations to disclose. (Updated 03/01/11)

Judith S. Currier, MD
Dr Currier has received research grants awarded to the University of California Los Angeles from Merck & Co, Inc. (Updated 03/04/11)

Carlos del Rio, MD
Dr del Rio has received research grants awarded to Emory University from Merck & Co, Inc, Schering-Plough Corp (now Merck & Co, Inc), and Sanofi Pasteur. (Updated 03/01/11)

Joel E. Gallant, MD, MPH
Dr Gallant has served as a consultant to or advisor to Bristol-Myers Squibb, Gilead Sciences, Inc, Merck & Co, Inc, Tibotec Therapeutics, and ViiV Healthcare. He has been a member of data and safety monitoring boards and endpoint adjudication committees for Gilead Sciences, Inc, and Sangamo Biosciences, Inc. Johns Hopkins University has been the recipient of research grants or contracts from Gilead Sciences, Inc. (Updated 03/01/11)

Roy M. Gulick, MD, MPH
Dr Gulick has served as a consultant to Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, MedImmune, LLC, Merck & Co, Inc, ViiV Healthcare, and ViroStatics, and as an investigator for research study grants (to Weill Cornell) from Merck & Co, Inc, Pfizer Inc, and Tibotec Therapeutics. (Updated 03/4/11)

Donna M. Jacobsen
Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 06/24/11)

Douglas D. Richman, MD
Dr Richman has been a consultant to Biota, Bristol-Myers Squibb, CHIMERx, Gen-Probe Inc, Gilead Sciences, Inc, Idenix Pharmaceuticals, Inc, Johnson & Johnson, Merck & Co, Inc, and Monogram Biosciences, Inc. He has been the recipient of research grants or contracts from Merck & Co, Inc. Dr Richman has been a stock options holder of CHIMERx and Idenix Pharmaceuticals, Inc. (Updated 03/01/11)

Michael S. Saag, MD
Dr Saag has received grants and research support from and/or has been a scientific advisor to Ardea Biosciences, Inc, Avexa Ltd, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Pain Therapeutics, Inc, Pfizer Inc, Tibotec Therapeutics, Vertex Pharmaceuticals, Inc, and ViiV Healthcare. (Updated 06/10/11)

Robert T. Schooley, MD
Dr Schooley has served as a consultant to Gilead Sciences, Inc, GlaxoSmithKline, Inhibitex, Inc, Johnson & Johnson Services, Inc, Laboratory Corporation of America, Merck & Co, Inc, Santaris Pharma, and Tobira Therapeutics. He has stock options for Achillion Pharmaceuticals, Inc. (Updated 05/12/11)

Paul A. Volberding, MD
Dr Volberding has served as a consultant to or on scientific or clinical advisory boards for Bristol-Myers Squibb, and Gilead Sciences, Inc. He has served on data and safety monitoring boards for Gilead Sciences, Inc, Merck & Co, Inc, and TaiMed Biologics. (Updated 06/09/11)

Course Faculty and Staff

Below are the disclosures of financial relationships of the faculty and program staff of this Web-based CME conference.

Dr Arora has no relevant financial affiliations to disclose. (Updated 06/20/11)

Dr Beal has no relevant financial affiliations to disclose. (Updated 06/20/11)

Dr Burke has no relevant financial affiliations to disclose. (Updated 06/20/11)

Dr Castro has no relevant financial affiliations to disclose. (Updated 06/10/11)

Dr Chander has no relevant financial affiliations to disclose. (Updated 06/06/11)

Dr Cheever has no relevant financial affiliations to disclose. (Updated 06/09/10)

Dr Clifford has received grants and research support from and/or been a scientific advisor to Biogen Idec, Bristol-Myers Squibb, Genentech, Inc, Genzyme, Millennium, Pfizer, Inc, and Wyeth. (updated 06/16/2011)

Dr Erbelding has no relevant financial affiliations to disclose. (Updated 08/11/10)

Dr Eron has received research grants awarded to University of North Carolina from GlaxoSmithKline/ViiV Healthcare, Merck & Co, Inc, and TaiMed Biologics. He has served as a consultant to Argos Therapeutics, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline/ViiV Healthcare, Merck & Co, Inc, Tibotec Therapeutics, and Tobira Therapeutics. (Updated 05/12/11)

Dr Hill has no relevant financial affiliations to disclose. (Updated 06/16/11)
Dr Marrazzo has received grants and research support from Cepheid Inc. She has served as a scientific advisor to Bayer Pharmaceuticals, Gilead Sciences, Inc, Graceway Pharmaceuticals, and Merck & Co, Inc. (Updated 06/21/11)

Dr Post has no relevant financial affiliations to disclose. (Updated 06/10/11)

Dr Ries has no relevant financial affiliations to disclose. (Updated 06/20/11)

Dr Ross has no relevant financial affiliations to disclose. (Updated 07/16/10)

Dr Saag has received grants and research support from and/or has been a scientific advisor to Ardea Biosciences, Inc, Avexa Ltd, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Pain Therapeutics, Inc, Pfizer Inc, Tibotec Therapeutics, Vertex Pharmaceuticals, Inc, and ViiV Healthcare. (Updated 06/10/11)

Dr Siliciano has no relevant financial affiliations to disclose. (Updated 06/20/11)

Dr Valcour has no relevant affiliations to disclose. (Updated 04/25/11)

Dr Wallenius has no relevant financial affiliations to disclose. (Updated 06/20/11)

Dr Wyatt has received research grants or contracts from Gilead Sciences, Inc. (Updated 06/21/11)


IAS–USA CME Staff

Donna M. Jacobsen, Executive Director, has no relevant financial affiliations to disclose (see above).

Cristin M. Toth, CME Project Associate, has no relevant financial affiliations to disclose. (Updated 06/24/11)

Program Development Committee

Dr Carmichael has no relevant financial affiliations to disclose. (Updated 03/01/11)

Ms Fullerton has no relevant financial affiliations to disclose. (Updated 06/20/11)

Ms Morgan has no relevant financial affiliations to disclose. (Updated 06/20/11)

Ms Palow has no relevant financial affiliations to disclose. (Updated 06/20/11)

Ms Richardson has no relevant financial affiliations to disclose. (Updated 06/20/11)

Ms Wegman has no relevant financial affiliations to disclose. (Updated 06/20/11)

Discussion of Investigational or Unapproved Usage

This activity presents an update on new research that may involve the use of investigational or unapproved drugs and therapies. Participants should consult the product information and other resources for comprehensive information on drugs and therapies discussed in the cases. The views and opinions expressed herein are those of the faculty and do not necessarily represent the opinions or recommendations of the HIV/AIDS Bureau, Health Resources and Services Administration of the US Department of Health and Human Services, the AIDS Education and Training Centers National Resource Center, and the IAS–USA.


Contact Information

If you have any questions about this Web-based CME activity, please contact the IAS –USA:

IAS–USA
425 California Street
Suite 1450
San Francisco, CA 94104-2120
Telephone: 415-544-9400
Fax: 415-544-9401
E-mail: registration2011@iasusa.org

I have read these instructions and understand them.